RCM
UTHR icon

Rotella Capital Management’s United Therapeutics UTHR Stock Holding History

Rotella Capital Management’s Portfolio UTHR Stock Details UTHR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q1 		– Sell
-3,000
Closed -$470K – 239
2015
Q4 		$470K Buy
+3,000
New +$437K 0.42% 35
2014
Q3 		– Sell
-2,500
Closed -$221K – 403
2014
Q2 		$221K Buy
+2,500
New +$240K 0.19% 99

Other funds holding UTHR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
AL
AJO LP Philadelphia, Pennsylvania $199M AUM 109.68% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Rotella Capital Management's UTHR Position: Q1 2016 in Review

Rotella Capital Management sold out of United Therapeutics (UTHR) in Q1 2016, closing a stake of 3,000 shares — an estimated $470K sold.

Rotella Capital Management first reported a position in UTHR in Q2 2014 and held it in 2 quarters. The position peaked at $470K in Q4 2015. 399 funds tracked by Wall St. Rank hold UTHR as of Q1 2016.

  • Rotella Capital Management reported no remaining United Therapeutics position as of Q1 2016 after selling out during the quarter.
  • Rotella Capital Management sold 3,000 United Therapeutics shares in Q1 2016, an estimated $470K.
  • Rotella Capital Management first reported a position in United Therapeutics in Q2 2014 and held it in 2 quarters.
  • Rotella Capital Management's United Therapeutics position peaked at $470K in Q4 2015.
  • 399 funds tracked by Wall St. Rank held United Therapeutics as of Q1 2016.

Based on Rotella Capital Management's 13F filing for Q1 2016, filed 13 May 2016.